KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Share-based Compensation (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Share-based Compensation data on record, last reported at $3.1 million in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 43.02% year-over-year to $3.1 million; the TTM value through Sep 2025 reached $15.3 million, down 36.59%, while the annual FY2024 figure was $21.6 million, 35.27% down from the prior year.
  • Share-based Compensation reached $3.1 million in Q3 2025 per NKTR's latest filing, down from $3.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $24.7 million in Q3 2021 and bottomed at $3.1 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $11.4 million, with a median of $8.1 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: rose 4.18% in 2021, then plummeted 53.18% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $22.4 million in 2021, then tumbled by 43.15% to $12.7 million in 2022, then tumbled by 43.05% to $7.3 million in 2023, then crashed by 33.79% to $4.8 million in 2024, then tumbled by 36.04% to $3.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $3.1 million in Q3 2025, $3.5 million in Q2 2025, and $3.9 million in Q1 2025.